SUMO-1 regulates body weight and adipogenesis via PPARγ in male and female mice

Endocrinology

Volumn 154, Issue 2, 2013, Pages 698-708

  Mikkonen, Laura ^a   Hirvonen, Johanna ^a   Jänne, Olli A ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SUMO 1 PROTEIN;

ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; DRUG EFFECT; FEMALE; GENE EXPRESSION; GLUCOSE TOLERANCE; GONAD; MALE; MOUSE; NONHUMAN; NULL CELL; PRIORITY JOURNAL; TRANSCRIPTION INITIATION;

3T3-L1 CELLS; ADIPOGENESIS; ADIPOSE TISSUE, WHITE; ANIMALS; BODY WEIGHT; DIET, HIGH-FAT; FEMALE; MALE; MICE; MICE, KNOCKOUT; PPAR GAMMA; SUMO-1 PROTEIN; THIAZOLIDINEDIONES;

EID: 84872724464     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1846     Document Type: Article

References (49)

1. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab. 2012;23:205-215.
2. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256-263. (Pubitemid 38196741)
3. Forman BM, Chen J, Evans RM. The peroxisome proliferator-activated receptors: ligands and activators. Ann N Y Acad Sci. 1997;804:266-275.
4. Krey G, Braissant O, L'Horset F, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 1997;11:779-791. (Pubitemid 27225305)
5. van Beekum O, Fleskens V, Kalkhoven E. Posttranslational modifications of PPAR-γ: fine-tuning the metabolic master regulator. Obesity (Silver Spring). 2009;17:213-219.
6. Gareau JR, Lima CD. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol. 2010;11:861-871.
7. Johnson ES. Protein modification by SUMO. Annu Rev Biochem. 2004;73:355-382. (Pubitemid 39050373)
8. Poukka H, Karvonen U, Jänne OA, Palvimo JJ. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci U S A. 2000;97:14145-14150. (Pubitemid 32016544)
9. Sentis S, Le Romancer M, Bianchin C, Rostan MC, Corbo L. Sumoylation of the estrogen receptor α hinge region regulates its transcriptional activity. Mol Endocrinol. 2005;19:2671-2684. (Pubitemid 41577242)
10. Gill G. Something about SUMO inhibits transcription. Curr Opin Genet Dev. 2005;15:536-541. (Pubitemid 41262410)
11. Gostissa M, Hengstermann A, Fogal V, et al. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J. 1999;18:6462-6471. (Pubitemid 29533250)
12. Hwang EJ, Lee JM, Jeong J, et al. SUMOylation of RORα potentiates transcriptional activation function. Biochem Biophys Res Commun. 2009;378:513-517.
13. Duverger O, Chen SX, Lee D, Li T, Chock PB, Morasso MI. SUMOylation of DLX3 by SUMO1 promotes its transcriptional activity. J Cell Biochem. 2011;112:445-452.
14. Ihara M, Yamamoto H, Kikuchi A. SUMO-1modification of PIASy, an E3 ligase, is necessary for PIASy-dependent activation of Tcf-4. Mol Cell Biol. 2005;25:3506-3518. (Pubitemid 40559558)
15. Choi JH, Banks AS, Kamenecka TM, et al. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature. 2011;477:477-481.
16. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science. 1996;274:2100-2103. (Pubitemid 27020707)
17. Yang XJ, Grégoire S. A recurrent phospho-sumoyl switch in transcriptional repression and beyond. Mol Cell. 2006;23:779-786. (Pubitemid 44344522)
18. Ohshima T, Koga H, Shimotohno K. Transcriptional activity of peroxisome proliferator-activated receptor γ is modulated by SUMO-1 modification. J Biol Chem. 2004;279:29551-29557. (Pubitemid 38915836)
19. Yamashita D, Yamaguchi T, Shimizu M, Nakata N, Hirose F, Osumi T. The transactivating function of peroxisome proliferator-activated receptor γ is negatively regulated by SUMO conjugation in the amino-terminal domain. Genes Cells. 2004;9:1017-1029. (Pubitemid 39467975)
20. Floyd ZE, Stephens JM. Control of peroxisome proliferator-activated receptor γ2 stability and activity by SUMOylation. Obes Res. 2004;12:921-928. (Pubitemid 41202392)
21. Pascual G, Fong AL, Ogawa S, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature. 2005;437:759-763. (Pubitemid 41486547)
22. Yang WH, Heaton JH, Brevig H, Mukherjee S, Iñiguez-Lluhí JA, Hammer GD. SUMOylation inhibits SF-1 activity by reducing CDK7-mediated serine 203 phosphorylation. Mol Cell Biol. 2009;29:613-625.
23. Lee FY, Faivre EJ, Suzawa M, et al. Eliminating SF-1 (NR5A1) sumoylation in vivo results in ectopic hedgehog signaling and disruption of endocrine development. Dev Cell. 2011;21:315-327.
24. Zhang FP, Mikkonen L, Toppari J, Palvimo JJ, Thesleff I, Jänne OA. Sumo-1 function is dispensable in normal mouse development. Mol Cell Biol. 2008;28:5381-5390.
25. Rosenthal N. Identification of regulatory elements of cloned genes with functional assays. Meth Enzymol. 1987;152:704-720.
26. Kang Z, Jänne OA, Palvimo JJ. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol. 2004;18:2633-2648. (Pubitemid 39482054)
27. Thompson J, Lepikhova T, Teixido-Travesa N, Whitehead M, Palvimo JJ, Jänne OA. Small carboxyl-terminal domain phosphatase 2 attenuates androgen-dependent transcription. EMBO J. 2006;25:2757-2767. (Pubitemid 43980383)
28. Nielsen R, Pedersen TA, Hagenbeek, et al. Genome-wide profiling of PPARγ:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes Dev. 2008;22:2953-2967.
29. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ. 1990;300:230-235. (Pubitemid 20045528)
30. Tempé D, Piechaczyk M, Bossis G. SUMO under stress. Biochem Soc Trans. 2008;36:874-878.
31. Fisher FM, Kleiner S, Douris N, et al. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012;26:271-281.
32. Vegiopoulos A, Müller-Decker K, Strzoda D, et al. Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes. Science. 2010;328:1158-1161.
33. Petrovic N, Walden TB, Shabalina IG, Timmons JA, Cannon B, Nedergaard J. Chronic peroxisome proliferator-activated receptor γ (PPARγ) activation of epididymally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic brown adipocytes. J Biol Chem. 2010;285:7153-7164.
34. Wu J, Boström P, Sparks LM, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell. 2012;150:366-376.
35. Rosen ED, Sarraf P, Troy AE, et al. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell. 1999;4:611-617. (Pubitemid 29531140)
36. Farmer SR. Transcriptional control of adipocyte formation. Cell Metab. 2006;4:263273.
37. Wu Z, Rosen ED, Brun R, et al. Cross-regulation of C/EBPα and PPARγ controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell. 1999;3:151-158. (Pubitemid 29292616)
38. Ghisletti S, Huang W, Ogawa S, et al. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARγ. Mol Cell. 2007;25:57-70. (Pubitemid 46049061)
39. Evdokimov E, Sharma P, Lockett SJ, Lualdi M, Kuehn MR. Loss of SUMO1 in mice affects RanGAP1 localization and formation of PML nuclear bodies, but is not lethal as it can be compensated by SUMO2 or SUMO3. J Cell Sci. 2008;121:41064113.
40. Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modification of IκBα inhibits NF-κB activation. Mol Cell. 1998;2:233-239. (Pubitemid 128373648)
41. Prudden J, Pebernard S, Raffa G, et al. SUMO-targeted ubiquitin ligases in genome stability. EMBO J. 2007;26:4089-4101. (Pubitemid 47462097)
42. Li P, Fan W, Xu J, et al. Adipocyte NCoR knockout decreases PPARγ phosphorylation and enhances PPARγ activity and insulin sensitivity. Cell. 2011;147:815-826.
43. Tiefenbach J, Novac N, Ducasse M, Eck M, Melchior F, Heinzel T. SUMOylation of the corepressor N-CoR modulates its capacity to repress transcription. Mol Biol Cell. 2006;17:1643-1651. (Pubitemid 44011582)
44. Picard N, Caron V, Bilodeau S, et al. Identification of estrogen receptor β as a SUMO-1 target reveals a novel phosphorylated sumoylation motif and regulation by glycogen synthase kinase 3β. Mol Cell Biol. 2012;32:2709-2721.
45. Abdel-Hafiz H, Takimoto GS, Tung L, Horwitz KB. The inhibitory function in human progesterone receptor N termini binds SUMO-1 protein to regulate autoinhibition and transrepression. J Biol Chem. 2002;277:33950-33956.
46. Hartig SM, He B, Newberg JY, et al. Feed-forward inhibition of androgen receptor activity by glucocorticoid action in human adipocytes. Chem Biol. 2012;19:1126-1141.
47. Lu M, Sarruf DA, Talukdar S, et al. Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med. 2011;17:618-622.
48. Venteclef N, Jakobsson T, Ehrlund A, et al. GPS2-dependent corepressor/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXRβ in the hepatic acute phase response. Genes Dev. 2010;24:381-395.
49. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994;8:1224-1234.